NAD allows P&G's "doctor recommended" claims
Procter & Gamble ads for Align probiotic supplement meet the National Advertising Division's high standards for making "doctor recommended" claims, the Council of Better Business Bureaus division says in a Sept. 14 release. NAD says it "closely scrutinizes these types of claims and requires highly reliable supporting evidence as substantiation" because doctor recommended claims "carry a great deal of weight with consumers." NAD found an independent survey by Wolters Kluwer adequately supports the claim "Align is the #1 gastroenterologist-recommended probiotic supplement that helps you build and maintain a stronger, healthier digestive system." The watchdog group notes P&G does not and should not say doctors recommend the product for specific symptoms. NAD also questioned claims that Align is "clinically proven" to protect against five signs of digestive imbalance. P&G volunteered to discontinue the claims - a move NAD says is "necessary and proper.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.